

WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Forty-third report



SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

WHO Technical Report Series — 953

The Expert Committee on Specifications for Pharmaceutical Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. Standards are developed by the Committee through worldwide consultation and an international consensus-building process.

The following new standards and guidelines were adopted and recommended for use: the current list of available International Chemical Reference Substances and International Infrared Reference Spectra; guidelines on stability testing of active pharmaceutical ingredients and finished pharmaceutical products; procedure for prequalification of pharmaceutical products; and the procedure for assessing the acceptability, in principle, of active pharmaceutical ingredients for use in pharmaceutical products.

ISBN 9789241209533



The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective — the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs CHF/US\$ 188.00 (CHF/US\$ 143.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order on line: <http://www.who.int/bookorders>).

SELECTED WHO PUBLICATIONS OF RELATED INTEREST

The International Pharmacopoeia, fourth edition.

Volume 1: general notices; monographs for pharmaceutical substances (A–O)

Volume 2: monographs for pharmaceutical substances (P–Z); monographs for dosage forms and radiopharmaceutical preparations; methods of analysis; reagents.

2006 (1500 pages), also available in CD-ROM format and on line

First supplement: general notices; monographs for pharmaceutical substances; monographs for dosage forms; general and specific monographs; methods of analysis; International Chemical Reference Substances; International Infrared Reference Spectra; reagents, test solutions and volumetric solutions.

2008 (309 pages)

Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms

1998 (94 pages)

Basic tests for pharmaceutical dosage forms

1991 (134 pages)

Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials

Volume 1: 1997 (244 pages)

Volume 2: good manufacturing practices and inspection.

Second updated edition, 2007 (409 pages)

Also available on: WHO training modules on GMP. A resource and study pack for trainers, 2007 (CD-ROM).

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Forty-second report.

WHO Technical Report Series, No. 948, 2008 (138 pages)

International nonproprietary names (INN) for pharmaceutical substances

Cumulative list no. 12

2007 (available in CD-ROM format only)

The selection and use of essential medicines

Report of the WHO Expert Committee (including the Model List of Essential Medicines for Children).

WHO Technical Report Series, No. 950, 2008 (174 pages)

WHO Expert Committee on Biological Standardization

Fifty-sixth report.

WHO Technical Report Series, No. 941, 2007 (340 pages)

Further information on these and other WHO publications can be obtained from
WHO Press, World Health Organization, 1211 Geneva 27, Switzerland
(tel. +41 22 791 3264; fax: +41 22 791 4857;
e-mail: bookorders@who.int; order on line: <http://www.who.int/bookorders>)

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization

WHO Technical Report Series

953

WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS

Forty-third report



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Forty-third report of the WHO Expert Committee on specifications for pharmaceutical preparations.

(WHO technical report series ; no. 953)

1. Pharmaceutical preparations - standards. 2. Technology, Pharmaceuticals - standards. 3. Drug industry - legislation. 4. Quality control. I. World Health Organization. II. Series.

ISBN 978 92 4 120953 3
ISSN 0512-3054

(NLM classification: QV 771)

© World Health Organization 2009

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

**Typeset in Switzerland
Printed in Switzerland**

Contents

| | |
|--|----|
| 1. Introduction | 1 |
| 2. General policy | 6 |
| 2.1 Collaboration with international organizations and agencies | 6 |
| 2.1.1 The Global Fund to Fight AIDS, Tuberculosis and Malaria | 6 |
| 2.1.2 Pharmacopoeial Discussion Group | 7 |
| 2.1.3 European Directorate for the Quality of Medicines and HealthCare | 9 |
| 2.1.4 European Medicines Agency | 10 |
| 2.1.5 International Pharmaceutical Federation | 10 |
| 2.1.6 United Nations Children's Fund | 11 |
| 2.1.7 World Intellectual Property Organization | 13 |
| 2.1.8 The World Bank | 14 |
| 2.1.9 International Conference on Harmonisation | 15 |
| 2.1.10 Medicines for children | 15 |
| 2.1.11 Counterfeit medicines | 17 |
| 2.1.12 International Conference of Drug Regulatory Authorities | 20 |
| 2.1.13 Regulatory support | 21 |
| 3. Joint session with the Expert Committee on Biological Standardization | 23 |
| 3.1 Transition from biological to chemical assay | 23 |
| 3.2 International Nonproprietary Names | 24 |
| 3.3 Quality assurance – good manufacturing practices for biologicals | 24 |
| 3.4 Quality control parameters and their relevance to International Standards | 24 |
| 3.5 Pharmaceutical cold chain – distribution of temperature sensitive vaccines | 25 |
| 4. Quality control – specifications and tests | 25 |
| 4.1 <i>The International Pharmacopoeia</i> | 25 |
| 4.2 Current work plan and future work programme | 26 |
| 4.3 Specifications for medicines, including children's medicines | 28 |
| 4.3.1 Medicines for HIV and related conditions | 29 |
| 4.3.2 Antimalarial medicines | 30 |
| 4.3.3 Antituberculosis medicines | 30 |
| 4.3.4 Other medicines | 30 |
| 4.4 Revision of texts of <i>The International Pharmacopoeia</i> | 31 |
| 4.4.1 Heparin | 31 |
| 4.4.2 Antibiotics | 32 |
| 4.4.3 Antimalarials: artemisinin derivatives | 33 |
| 4.4.4 Excipients | 33 |
| 4.5 General monographs for dosage forms and associated method texts | 34 |
| 4.6 Radiopharmaceuticals | 34 |
| 4.6.1 General monograph and related texts | 35 |
| 4.6.2 Individual monographs | 35 |

| | |
|--|-----------|
| 5. Quality control – International Reference materials (International Chemical Reference Substances and International Infrared Reference Spectra) | 37 |
| 5.1 Annual reports of the WHO Collaborating Centre | 37 |
| 5.2 Adoption of new International Chemical Reference Substances | 38 |
| 5.3 International Infrared Reference Spectra | 38 |
| 6. Quality control – National laboratories | 38 |
| 6.1 External Quality Assurance Assessment Scheme | 38 |
| 6.2 WHO good practices for national quality control laboratories | 40 |
| 7. Quality assurance – Good manufacturing practices | 42 |
| 7.1 Good manufacturing practices for biologicals | 42 |
| 7.2 Guidance on the inspection of hormone product manufacturing facilities | 43 |
| 8. Quality Assurance – new approaches and risk analysis | 44 |
| 8.1 Information sharing and collaboration | 44 |
| 8.2 WHO guideline on transfer of technology | 47 |
| 9. Quality assurance – distribution and trade of pharmaceuticals | 47 |
| 9.1 WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce | 47 |
| 9.2 WHO good distribution practices for pharmaceutical products (proposal for revision by the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) partnership) | 49 |
| 10. Quality assurance – stability | 50 |
| 11. Prequalification of priority essential medicines and devices | 53 |
| 11.1 Prequalification Programme managed by WHO | 53 |
| 11.2 Procedure for prequalification of pharmaceutical products | 54 |
| 12. Prequalification of quality control laboratories | 54 |
| 13. Prequalification of active pharmaceutical ingredients | 55 |
| 13.1 Procedure for prequalification of active pharmaceutical ingredients | 55 |
| 14. Regulatory guidance | 55 |
| 14.1 Specific regulatory guidance on paediatric medicines | 55 |
| 14.2 Guidelines for pharmaceutical development of generics | 56 |
| 14.3 Quality of herbal and complementary medicines | 57 |
| 14.4 List of comparator products | 57 |
| 15. Nomenclature, terminology and databases | 57 |
| 15.1 Quality assurance terminology | 57 |
| 15.2 International Nonproprietary Names | 58 |
| 15.3 Pharmacopoeial references | 59 |

| | |
|---|-----------|
| 16. Miscellaneous | 59 |
| 16.1 Draft WHO Medicines Strategy 2008—2013 | 59 |
| 16.2 Follow-up activities on “biowaiver” | 60 |
| 16.3 Promotional brochure | 61 |
| 16.4 Model quality assurance system for procurement agencies | 61 |
| 17. Summary and recommendations | 62 |
| Acknowledgements | 69 |
| Annex 1 | |
| List of available International Chemical Reference Substances and International Infrared Reference Spectra | 75 |
| Annex 2 | |
| Stability testing of active pharmaceutical ingredients and finished pharmaceutical products | 87 |
| Annex 3 | |
| Procedure for prequalification of pharmaceutical products | 131 |
| Annex 4 | |
| Procedure for assessing the acceptability, in principle, of active pharmaceutical ingredients for use in pharmaceutical products | 149 |



预览已结束，完整报告链接和二

<https://www.yunbaogao.cn/report/index/report?re>

